The Mucin 16 (MUC16) antigen has been reported in 70% of ovarian cancer and a clinical trial is also evaluating the efficacy and safety of CAR-T cells targeting MUC16 after standard chemotherapy [130]. Here, MUC16 is linked to ovarian carcinoma.